Shopping Cart
Remove All
Your shopping cart is currently empty
Naxitamab (Synonyms: Naxitamab-gqgk, Humanized 3F8, Hu3F8)
Catalog No. T77448 Copy Product Info
🥰Excellent
Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting GD2 with antitumor activity, used to study neuroblastoma, osteosarcoma, and other GD2-positive cancers.
Naxitamab
Copy Product Info🥰Excellent
Catalog No. T77448
Synonyms Naxitamab-gqgk, Humanized 3F8, Hu3F8
Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting GD2 with antitumor activity, used to study neuroblastoma, osteosarcoma, and other GD2-positive cancers.
Naxitamab
Cas No. 1879925-92-4
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $189 | In Stock | In Stock | |
| 5 mg | $476 | In Stock | In Stock | |
| 10 mg | $788 | - | In Stock | |
| 25 mg | $1,180 | - | In Stock | |
| 50 mg | $1,590 | - | In Stock | |
| 100 mg | $2,130 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:100% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting GD2 with antitumor activity, used to study neuroblastoma, osteosarcoma, and other GD2-positive cancers. |
| Targets&IC50 | LAN1:5.1 μg/mL |
| In vitro | Naxitamab (Hu3F8; 72 h) exhibits cytotoxicity against the neuroblastoma cell line LAN-1, with an EC50 value of 5.1 μg/mL[1]. Naxitamab (0.1-1 μg/mL; 4 h; peripheral blood mononuclear cells (PBMC) and polymorphonuclear leukocytes (PMN)) demonstrates antibody-dependent cell-mediated cytotoxic effects (ADCC)[1]. |
| In vivo | In athymic nude mice with LAN-1 xenografts, Naxitamab (Hu3F8; 100 mg/kg; intravenous; twice a week for 4 weeks) inhibits tumor growth in neuroblastoma xenografts[1]. |
| Synonyms | Naxitamab-gqgk, Humanized 3F8, Hu3F8 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | GD2 |
| Molecular Weight | 144.38 kDa |
| Cas No. | 1879925-92-4 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Keywords
Preview
Related Tags: buy Naxitamab | purchase Naxitamab | Naxitamab cost | order Naxitamab | Naxitamab in vivo | Naxitamab in vitro | Naxitamab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.